LeMaitre shares fall after Q1 earnings despite higher sales, margin guidance

LeMaitre Vascular Inc. (LMAT) shares traded at $101.82 as of May 15, 2026, down from about $112 before its first-quarter earnings report, as investors weighed operational concerns against double-digit sales growth and margin expansion. Management said growth was driven by core product lines, pricing discipline and international demand for Artegraft. CEO George LeMaitre said worldwide Artegraft sales rose 36% in the quarter, with product and geographic expansion contributing to results. The company raised its annual gross margin guidance to 72.3%, CFO Dorian LeBlanc said, citing margin improvement and direct-to-hospital sales execution. Investors are watching Artegraft launches in Canada and other regions, regulatory filings, direct market entries in Canada and Poland, salesforce expansion, and whether margins can hold as the company increases operational investment.